Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 5/20 | 0.53 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.42 |
| ▸ | ALAD | P13716 | 1/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4433275 | 0.84 | DAO (0.59) | DAOC3AR1PTGDR2 | |
| SCHEMBL4432455 | 0.84 | DAO (0.58) | DAOC3AR1ALDH1A1HPGD | |
| SCHEMBL4438845 | 0.83 | DAO (0.53) | DAOC3AR1ALDH1A1HPGD | |
| SCHEMBL4437601 | 0.81 | C3AR1 (0.54) | DAOC3AR1ALDH1A1HPGDMRGPRX4 | |
| SCHEMBL4433839 | 0.77 | HDAC3 (0.47) | C3AR1ALDH1A1HPGD | |
| SCHEMBL4432196 | 0.73 | DAO (0.50) | DAOALDH1A1HPGD | |
| SCHEMBL4439617 | 0.71 | DAO (0.51) | DAOC3AR1PTGDR2CNR2 | |
| SCHEMBL6470934 | 0.70 | HDAC3 (0.62) | FFAR2ALDH1A1HPGD | |
| SCHEMBL6461129 | 0.70 | HDAC3 (0.62) | FFAR2ALDH1A1HPGD | |
| SCHEMBL2141423 | 0.70 | DAO (0.64) | DAOALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125739-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008079371-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | DAO 1635/4885C3AR1 1/4885P2RY2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.